Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Arcus Biosciences Inc shares valued at $913,027 were sold by Jaen Juan C. on Nov 17 ’25. At $20.31 per share, Jaen Juan C. sold 44,950 shares. The insider’s holdings dropped to 1,042,110 shares worth approximately $22.12 million following the completion of this transaction.
Also, Jaen Juan C. sold 5,050 shares, netting a total of over 99,738 in proceeds. Following the sale of shares at $19.75 each, the insider now holds 1,037,060 shares.
Before that, Juan Jaen had added 50,000 shares to its account. In a trade valued at $999,500, the Officer bought Arcus Biosciences Inc shares for $19.99 each.
As published in a research note from H.C. Wainwright on February 26, 2025, Arcus Biosciences Inc [RCUS] has been rated up from a Neutral to a Buy and the price target has been revised to $24 from $18. Analysts at H.C. Wainwright started covering the stock with ‘”a Neutral”‘ outlook in a report released in late October. As of October 08, 2024, Wells Fargo has initiated its “an Overweight” rating for RCUS. Earlier on November 18, 2022, BofA Securities initiated its rating. Their recommendation was “a Neutral” for RCUS stock.
Analyzing RCUS Stock Performance
On last trading session, Arcus Biosciences Inc [NYSE: RCUS] rose 5.00% to $21.23. The stock’s lowest price that day was $20.5, but it reached a high of $21.55 in the same session. During the last five days, there has been a surge of approximately 7.28%. Over the course of the year, Arcus Biosciences Inc shares have jumped approximately 47.12%. Shares of the company reached a 52-week high of $22.11 on 10/29/25 and a 52-week low of $6.50 on 04/07/25.
Support And Resistance Levels for Arcus Biosciences Inc (RCUS)
According to the 24-hour chart, there is a support level at 20.64, which, if violated, would cause prices to drop to 20.04. In the upper region, resistance lies at 21.69. The next price resistance is at 22.14. RSI (Relative Strength Index) is 71.56 on the 14-day chart, showing overbought technical sentiment.
Is Arcus Biosciences Inc subject to short interest?
Stocks of Arcus Biosciences Inc saw a sharp steep in short interest on 2025-10-31 dropping by -1.55 million shares to 8.34 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 9.89 million shares. A decline of -18.54% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.41 of the overall float, the days-to-cover ratio (short ratio) decline to 5.41.
Which companies own the most shares of Arcus Biosciences Inc (RCUS)?
In terms of Arcus Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 31.5 in the next 12 months, up nearly 55.79% from the previous closing price of $20.22. Analysts anticipate Arcus Biosciences Inc stock to reach 39 by 2025, with the lowest price target being 16. In spite of this, 3 analysts ranked Arcus Biosciences Inc stock as Buy at the end of 2025. On October 11, 2022, Morgan Stanley assigned a price target of “an Overweight” to the stock and initiated coverage with a $40.
